Isogenica uses its proprietary

technology CIS display to discover novel

biologics against a wide variety of target

proteins including intractable and

difficult targets such as membrane proteins,

membranes and cells.

Biologically active polypeptides and affinity

reagents have been identified potentially

serving as leads in pharmacophore or

pathway discovery, in therapeutic programs

or as diagnostic tools.